logo
Plus   Neg
Share
Email

Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences

Bristol-Myers Squibb Co (BMY) announced that it has won jury verdict against Gilead Sciences Inc (GILD) in a U.S. patent dispute relating to technology for treating cancer.

A jury in Los Angeles ordered Gilead's Kite Pharma to pay $752 million to Bristol-Myers Squibb' Juno Therapeutics division, which sued in 2017 for patent infringement.

In its lawsuit, Juno alleged Kite scientific collaborators copied research by scientists at Sloan Kettering to advance Kite's CAR-T work and eventually win approval for Yescarta.

"We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," Gilead said in a statement. "Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages."

A BMS spokesperson said the company is pleased with the decision and Gilead said it expected to seek to undo the verdict through post-trial motions and a potential appeal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT